Dicot Pharma AB: The subscription period in Dicot Pharma's rights issue begins today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

Today, August 16, 2024, the subscription period begins in Dicot Pharma AB (publ) ("Dicot") ongoing rights issue which is carried out with the main purpose of financing the upcoming phase 2a study with the potency drug candidate LIB-01. The subscription period continues until August 30, 2024. Subscription is made primarily through the exercise of unit rights that existing shareholders as of August 14, 2024, received based on preferential right, but shareholders and the public can also apply interest in subscription of units without the support of unit rights. Allocation will be made in accordance with the principles stated in the prospectus (Sw. EU-Tillväxtprospekt) that Dicot published on August 14, 2024.

By buying unit rights, it is possible to subscribe to more than what the preferential right of the original holding allows. Trading in unit rights, which give preferential right to the subscription of units, takes place during the period August 16-27, 2024 on Spotlight Stock Market.

Note that some nominees close the subscription period for the exercise of unit rights before August 30, 2024, and may sell unit rights for which the investor to the nominee has not provided a decision before August 27, 2024. Therefore, contact your bank or nominee in good time to find out which final dates that applies to the holding in your share account.

Procedure for subscription

How you notify of subscription of units in the Rights Issue depends on whether you are a directly registered shareholder or a nominee-registered shareholder. If you are unsure which, please contact your bank.

You have custody with a bank or securities institute (nominee-registered shareholder)

• Nominee-registered shareholders must contact their nominee for instructions and dates that apply to the specific nominee and act in accordance with these instructions. The instructions can often be found in a logged-in mode with your nominee.
• Application for subscription of units without the support of unit rights is made in accordance with the respective nominee's routines or via the Aqurat Fondkommission's website, www.aqurat.se.

You have a VP account (directly registered shareholder)

• If you exercise all unit rights, use the pre-printed bank giro notice from Euroclear Sweden and act in accordance with the instructions on it. If a different number of unit rights is to be exercised for subscription than what appears on the pre-printed notice, the special application form, sent out with the issue report and which can also be ordered from Aqurat Fondkommission, must be used.
• Application for subscription of units without the support of unit rights is made through the application form for subscription without preferential rights, which is available via the Aqurat Fondkommission's website, www.aqurat.se.

Advisors

Corpura Fondkommission AB acts as Global Coordinator and Joint Bookrunner together with Penser by Carnegie, Carnegie Investment Bank AB (publ) in connection to the Rights Issue, and Advokatfirman Lindahl KB is legal adviser.

For further information, please contact:

Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot Pharma is listed on Spotlight Stock Market and has approximately 6,100 shareholders. For more information, please visit www.dicotpharma.com.

Important Information

The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Dicot. No action has been taken and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden. The invitation to interested persons to subscribe for shares in Dicot takes place solely through the prospectus that the Company has published.

The information contained in this press release may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for securities in the United States. No shares, subscription rights or other securities issued by the Company ("Securities") have been registered, and no shares or other Securities will be registered, under the United States Securities Act of 1933 from time to time ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, subscribed, exercised, pledged, sold or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to the securities laws of the relevant state or other jurisdiction in the United States. The securities have not been approved or registered, and will not be approved or registered, by the U.S. Securities and Exchange Commission, any state securities regulator or any other authority in the United States. Nor has any such authority assessed or commented on the offering or the accuracy and reliability of the prospectus. To say the opposite is a criminal offense in the United States.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. In an EEA Member State, other than Sweden, this announcement is only intended for and is only directed at "qualified investors" in the respective Member State within the meaning of the Prospectus Regulation.

In the United Kingdom, this document, and other materials relating to the securities referred to herein, are distributed and directed only to, and an investment or investment activity attributable to this document is only available to and will only be able to be exercised by "qualified investors" (in a sense in the UK version of Regulation (EU) 2017/1129 which is part of UK legislation by the European Union (Withdrawal) Act 2018) who are (i) persons who have professional experience in dealings relating to investments and who fall within the definition of " investment professionals" in Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Regulation"); (ii) "high net worth entities" etc. as referred to in Article 49(2)(a)-(d) of the Regulation; or (iii) such other persons to whom such investment or investment activity may lawfully be directed under the Regulations (all such persons are collectively referred to as "relevant persons"). An investment or an investment measure to which this notice relates is available in the United Kingdom only to relevant persons and will only be carried out with relevant persons. Persons who are not relevant persons shall not take any action based on this document nor act or rely on it.